Vyant Bio’s Human First Drug Discovery Platform

Platform and Poster Presentations

Progress on CDKL5 Deficiency Disorder (CDD)

Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’s proprietary central nervous system (CNS) platform integrates machine learning and biology to accelerate the discovery of novel therapeutics for conditions such as CDKL5 Deficiency Disorder (CDD).

Vyant Bio recently announced their participation at the 2022 CDKL5 Forum, hosted by the Loulou Foundation. During this event, Vyant Bio presented platform and poster presentations highlighting the latest advancements in their drug discovery efforts for CDD. The Company’s commitment to putting patients first and focusing on unmet medical needs is evident in their approach to developing targeted therapies for rare and devastating conditions like CDD.

CDKL5 Deficiency Disorder is a rare genetic disorder that primarily affects the central nervous system, causing severe neurodevelopmental impairment and seizures. Currently, there are no approved treatments specifically for CDD, making it a critical area of unmet medical need. Vyant Bio’s dedication to advancing research and developing potential therapies for CDD is a significant step forward in improving the lives of those affected by this debilitating condition.

How This Will Affect You

For individuals and families impacted by CDKL5 Deficiency Disorder, Vyant Bio’s progress in drug discovery could offer hope for the development of effective treatments that could improve quality of life and potentially even change the course of the disease. As Vyant Bio continues to advance their research in this area, it is possible that new therapeutic options may become available in the future.

How This Will Affect the World

The groundbreaking work being done by Vyant Bio in the field of drug discovery for neurodevelopmental disorders has the potential to have far-reaching impacts on the global healthcare landscape. By focusing on rare and challenging conditions like CDKL5 Deficiency Disorder, Vyant Bio is paving the way for innovative approaches to drug development that could benefit not only those directly affected by these disorders but also society as a whole.

Conclusion

Vyant Bio’s participation at the 2022 CDKL5 Forum and their ongoing efforts in drug discovery for rare neurological disorders like CDD demonstrate their commitment to making a positive impact on the lives of patients. Through their innovative Human First Drug Discovery Platform, Vyant Bio is positioning themselves as a leader in the development of targeted therapies for complex conditions, bringing hope to those in need and driving progress in the field of biotechnology.